Top Midday Decliners

MT Newswires Live11-30

Applied Therapeutics (APLT) late Wednesday said the US Food and Drug Administration has issued a complete response letter indicating its decision to not approve a new drug application for the company's govorestat drug candidate to treat galactosemia, citing "deficiencies in the clinical application."

Applied Therapeutics plunged almost 76% on Friday as volume swelled to more than 40.3 million shares compared to a daily average of about 3 million shares traded daily.

Aptevo Therapeutics (APVO) said on Friday it expects to execute a 1-for-37 reverse split of its common shares following the close of Tuesday's regular session in a bid to lift its stock price back above the Nasdaq minimum of $1 per share.

The biotechnology company's shares recently were down nearly 19%, staying just above its intraday low. More than 2.4 million shares had traded late in Friday's holiday-shortened session compared with an average of more than 6.9 million shares exchanged every day.

RumbleOn (RMBL) received a downgrade to neutral from buy by analysts at B. Riley Securities, who maintained its $7 price target. The analysts noted that they expect most potential buyers to remain on the sidelines until there is a more significant drop in interest rates and the outlook for the US economy improves further

RumbleOn shares were down 3.1%, partially recovering from a nearly 7% decline soon after Friday's opening bell. Trading volume was moderate, with more than 87,000 shares changing hands compared with a daily average of nearly 106,000 shares per day.

Price: 2.08, Change: -6.49, Percent Change: -75.73

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment